KRTX — Karuna Therapeutics Share Price
0.000.00%
Last trade - 00:00- $12.58bn
- $11.32bn
- $0.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.03 | ||
| Price to Tang. Book | 10.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19,238.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.02% | ||
| Return on Equity | -36.44% | ||
| Operating Margin | -75653.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 36.96 | 10.64 | 0.65 | 38.56 | 272.47 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
Directors
- Steven Paul CHM (70)
- Troy Ignelzi CFO (54)
- Andrew Miller COO (39)
- Stephen Brannan OTH (64)
- Charmaine Lykins OTH
- Jeffrey Jonas DRC (68)
- Christopher Coughlin IND (68)
- James Healy IND (56)
- Laurie Olson IND (58)
- Atul Pande IND (66)
- Denice Torres IND (61)
- David Wheadon IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 24th, 2009
- Public Since
- June 28th, 2019
- No. of Shareholders
- 4
- No. of Employees
- 339
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 38,199,272
- Address
- 99 High Street, 26Th Floor, BOSTON, 02110
- Web
- https://karunatx.com/
- Phone
- +1 8574492244
- Auditors
- KPMG LLP
Upcoming Events for KRTX
Karuna Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Karuna Therapeutics Inc Earnings Release
Similar to KRTX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Karuna Therapeutics share price?
As of Today at 18:12 UTC, shares in Karuna Therapeutics are trading at $329.83. This share price information is delayed by 15 minutes.
How has the Karuna Therapeutics share price performed this year?
Shares in Karuna Therapeutics last closed at $329.83 and the price had moved by +74.2% over the past 365 days. In terms of relative price strength the Karuna Therapeutics share price has outperformed the S&P500 Index by +33.33% over the past year.
What are the analyst and broker recommendations for Karuna Therapeutics?
The overall consensus recommendation for Karuna Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Karuna Therapeutics dividend yield?
Karuna Therapeutics does not currently pay a dividend.
Does Karuna Therapeutics pay a dividend?
Karuna Therapeutics does not currently pay a dividend.
When does Karuna Therapeutics next pay dividends?
Karuna Therapeutics does not currently pay a dividend.
How do I buy Karuna Therapeutics shares?
To buy shares in Karuna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Karuna Therapeutics?
As of the previous close price of $329.83, shares in Karuna Therapeutics had a market capitalisation of $12.58bn.
Where are Karuna Therapeutics shares listed?
Here are the trading details for Karuna Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KRTX
What kind of share is Karuna Therapeutics?
Based on an overall assessment of its quality, value and momentum Karuna Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Karuna Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Karuna Therapeutics is $322.67. That is 2.17% below the last closing price of $329.83.
Analysts covering Karuna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$11.83 for the next financial year.
Find out moreWhat is the trend in the Karuna Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Karuna Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +58.68%.
As of the last closing price of $329.83, shares in Karuna Therapeutics were trading +44.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Karuna Therapeutics PE Ratio?
The Karuna Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $329.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Karuna Therapeutics?
Karuna Therapeutics' management team is headed by:
- Steven Paul - CHM
- Troy Ignelzi - CFO
- Andrew Miller - COO
- Stephen Brannan - OTH
- Charmaine Lykins - OTH
- Jeffrey Jonas - DRC
- Christopher Coughlin - IND
- James Healy - IND
- Laurie Olson - IND
- Atul Pande - IND
- Denice Torres - IND
- David Wheadon - IND